TipRanks
Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
US Market
GPCR
Structure Therapeutics, Inc. Sponsored ADR
RESEARCH TOOLSreports
Want to see GPCR full AI Analyst Report?

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Stock Forecast & Price Target

1,302 Followers
See the Price Targets and Ratings of:

GPCR Analyst Ratings

Strong Buy
14Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
Based on 14 analysts giving stock ratings to
Structure
Therapeutics, Inc. Sponsored ADR
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GPCR Stock 12 Month Forecast

Average Price Target

$108.46
▲(117.27% Upside)
Based on 14 Wall Street analysts offering 12 month price targets for Structure Therapeutics, Inc. Sponsored ADR in the last 3 months. The average price target is $108.46 with a high forecast of $145.00 and a low forecast of $70.00. The average price target represents a 117.27% change from the last price of $49.92.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","146":"$146","50.75":"$50.8","82.5":"$82.5","114.25":"$114.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":108.46153846153847,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$108.46</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,50.75,82.5,114.25,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.13,54.65846153846154,62.18692307692308,69.71538461538462,77.24384615384616,84.77230769230769,92.30076923076923,99.82923076923078,107.3576923076923,114.88615384615386,122.41461538461539,129.94307692307692,137.47153846153847,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.13,51.847810650887574,56.56562130177515,61.283431952662724,66.0012426035503,70.71905325443788,75.43686390532545,80.15467455621302,84.8724852071006,89.59029585798817,94.30810650887574,99.02591715976331,103.74372781065088,{"y":108.46153846153847,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.13,48.88923076923077,50.64846153846154,52.40769230769231,54.16692307692308,55.926153846153845,57.68538461538462,59.44461538461539,61.20384615384616,62.963076923076926,64.7223076923077,66.48153846153846,68.24076923076923,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":20.08,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.04,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.57,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.84,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.9,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.17,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.21,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.55,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.12,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.04,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.13,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$145.00Average Price Target$108.46Lowest Price Target$70.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on GPCR
Edward Nash
Canaccord Genuity
Canaccord Genuity
$111
Buy
122.36%
Upside
Reiterated
09/09/26
Canaccord Genuity Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
H.C. Wainwright Analyst forecast on GPCR
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$70
Buy
40.22%
Upside
Reiterated
09/09/26
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Belite Bio, Inc. ADR (NASDAQ: BLTE) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)
William Blair Analyst forecast on GPCR
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
LifeSci Capital Analyst forecast on GPCR
Patrick Dolezal
LifeSci Capital
LifeSci Capital
$104
Buy
108.33%
Upside
Reiterated
09/08/26
Structure Therapeutics: Buy Rating Reaffirmed on Promising Obesity Pipeline and Extended Data, Price Target Maintained at $104
Clear Street Analyst forecast on GPCR
Kaveri Pohlman
Clear Street
Clear Street
$99
Buy
98.32%
Upside
Reiterated
09/08/26
Structure obesity portfolio updates 'encouraging,' says Clear StreetStructure obesity portfolio updates 'encouraging,' says Clear Street
Jefferies Analyst forecast on GPCR
Roger Song
Jefferies
Jefferies
$125
Buy
150.40%
Upside
Reiterated
09/08/26
Structure weakness 'disconnected' from underlying data, says JefferiesStructure weakness 'disconnected' from underlying data, says Jefferies
J.P. Morgan Analyst forecast on GPCR
Hardik Parikh
J.P. Morgan
J.P. Morgan
$100
Buy
100.32%
Upside
Reiterated
08/17/26
J.P. Morgan Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Morgan Stanley Analyst forecast on GPCR
Terence Flynn
Morgan Stanley
Morgan Stanley
$126
Buy
152.40%
Upside
Assigned
08/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (NASDAQ: OCS), Stevanato Group (NYSE: STVN) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)
Citi Analyst forecast on GPCR
Samantha Semenkow
Citi
Citi
$100→$97
Buy
94.31%
Upside
Reiterated
08/10/26
Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)
Guggenheim Analyst forecast on GPCR
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$140
Buy
180.45%
Upside
Reiterated
08/07/26
Guggenheim Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Piper Sandler Analyst forecast on GPCR
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$93
Buy
86.30%
Upside
Reiterated
08/07/26
Piper Sandler Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Citizens JMP Analyst forecast on GPCR
Jonathan Wolleben
Citizens JMP
Citizens JMP
$113→$110
Buy
120.35%
Upside
Reiterated
08/07/26
Structure Therapeutics price target lowered to $110 from $113 at CitizensStructure Therapeutics price target lowered to $110 from $113 at Citizens
Stifel Nicolaus Analyst forecast on GPCR
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$90
Buy
80.29%
Upside
Reiterated
08/07/26
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Stifel Nicolaus
BMO Capital Analyst forecast on GPCR
Evan Seigerman
BMO Capital
BMO Capital
$145
Buy
190.46%
Upside
Reiterated
08/06/26
BMO Capital Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Cantor Fitzgerald Analyst forecast on GPCR
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
$101
Buy
102.32%
Upside
Reiterated
06/07/26
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Cabaletta Bio (NASDAQ: CABA) and Hinge Health, Inc. Class A (NYSE: HNGE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on GPCR
Edward Nash
Canaccord Genuity
Canaccord Genuity
$111
Buy
122.36%
Upside
Reiterated
09/09/26
Canaccord Genuity Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
H.C. Wainwright Analyst forecast on GPCR
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$70
Buy
40.22%
Upside
Reiterated
09/09/26
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Belite Bio, Inc. ADR (NASDAQ: BLTE) and BridgeBio Oncology Therapeutics (NASDAQ: BBOT)
William Blair Analyst forecast on GPCR
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Analysts Are Bullish on These Healthcare Stocks: enGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
LifeSci Capital Analyst forecast on GPCR
Patrick Dolezal
LifeSci Capital
LifeSci Capital
$104
Buy
108.33%
Upside
Reiterated
09/08/26
Structure Therapeutics: Buy Rating Reaffirmed on Promising Obesity Pipeline and Extended Data, Price Target Maintained at $104
Clear Street Analyst forecast on GPCR
Kaveri Pohlman
Clear Street
Clear Street
$99
Buy
98.32%
Upside
Reiterated
09/08/26
Structure obesity portfolio updates 'encouraging,' says Clear StreetStructure obesity portfolio updates 'encouraging,' says Clear Street
Jefferies Analyst forecast on GPCR
Roger Song
Jefferies
Jefferies
$125
Buy
150.40%
Upside
Reiterated
09/08/26
Structure weakness 'disconnected' from underlying data, says JefferiesStructure weakness 'disconnected' from underlying data, says Jefferies
J.P. Morgan Analyst forecast on GPCR
Hardik Parikh
J.P. Morgan
J.P. Morgan
$100
Buy
100.32%
Upside
Reiterated
08/17/26
J.P. Morgan Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Morgan Stanley Analyst forecast on GPCR
Terence Flynn
Morgan Stanley
Morgan Stanley
$126
Buy
152.40%
Upside
Assigned
08/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (NASDAQ: OCS), Stevanato Group (NYSE: STVN) and Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR)
Citi Analyst forecast on GPCR
Samantha Semenkow
Citi
Citi
$100→$97
Buy
94.31%
Upside
Reiterated
08/10/26
Analysts Are Bullish on These Healthcare Stocks: Immix Biopharma (IMMX), Ardelyx (ARDX)
Guggenheim Analyst forecast on GPCR
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
$140
Buy
180.45%
Upside
Reiterated
08/07/26
Guggenheim Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Piper Sandler Analyst forecast on GPCR
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$93
Buy
86.30%
Upside
Reiterated
08/07/26
Piper Sandler Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Citizens JMP Analyst forecast on GPCR
Jonathan Wolleben
Citizens JMP
Citizens JMP
$113→$110
Buy
120.35%
Upside
Reiterated
08/07/26
Structure Therapeutics price target lowered to $110 from $113 at CitizensStructure Therapeutics price target lowered to $110 from $113 at Citizens
Stifel Nicolaus Analyst forecast on GPCR
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$90
Buy
80.29%
Upside
Reiterated
08/07/26
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Stifel Nicolaus
BMO Capital Analyst forecast on GPCR
Evan Seigerman
BMO Capital
BMO Capital
$145
Buy
190.46%
Upside
Reiterated
08/06/26
BMO Capital Sticks to Their Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Cantor Fitzgerald Analyst forecast on GPCR
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
$101
Buy
102.32%
Upside
Reiterated
06/07/26
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (NASDAQ: GPCR), Cabaletta Bio (NASDAQ: CABA) and Hinge Health, Inc. Class A (NYSE: HNGE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
MDWDMediwound
OVIDOvid Therapeutics
CELCCelcuity
ONCBeOne Medicines
GHGuardant Health
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Structure Therapeutics, Inc. Sponsored ADR

3 Months
Andy HsiehWilliam Blair
Success Rate
5/12 ratings generated profit
42%
Average Return
+10.67%
Copying Andy Hsieh's trades and holding each position for 3 Months would result in 41.67% of your transactions generating a profit, with an average return of +10.67% per trade.
1 Year
Ananda GhoshH.C. Wainwright
Success Rate
9/17 ratings generated profit
53%
Average Return
+43.52%
Copying Ananda Ghosh's trades and holding each position for 1 Year would result in 52.94% of your transactions generating a profit, with an average return of +43.52% per trade.
2 Years
Yasmeen RahimiPiper Sandler
Success Rate
11/16 ratings generated profit
69%
Average Return
+17.11%
Copying Yasmeen Rahimi's trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +17.11% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GPCR Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
16
10
8
15
17
Buy
4
3
3
4
3
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
13
11
19
20
In the current month, GPCR has received 20 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. GPCR average Analyst price target in the past 3 months is 108.46.
Each month's total comprises the sum of three months' worth of ratings.

GPCR Financial Forecast

GPCR Earnings Forecast

Next quarter’s earnings estimate for GPCR is -$0.33 with a range of -$0.59 to $2.02. The previous quarter’s EPS was -$0.49. GPCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GPCR has Performed in-line its overall industry.
Next quarter’s earnings estimate for GPCR is -$0.33 with a range of -$0.59 to $2.02. The previous quarter’s EPS was -$0.49. GPCR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year GPCR has Performed in-line its overall industry.
No data currently available

GPCR Sales Forecast

Next quarter’s sales forecast for GPCR is $50.00M with a range of $0.00 to $500.00M. The previous quarter’s sales results were $0.00. GPCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GPCR has Performed in-line its overall industry.
Next quarter’s sales forecast for GPCR is $50.00M with a range of $0.00 to $500.00M. The previous quarter’s sales results were $0.00. GPCR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year GPCR has Performed in-line its overall industry.

GPCR Stock Forecast FAQ

What is GPCR’s average 12-month price target, according to analysts?
Based on analyst ratings, Structure Therapeutics, Inc. Sponsored ADR’s 12-month average price target is 108.46.
    What is GPCR’s upside potential, based on the analysts’ average price target?
    Structure Therapeutics, Inc. Sponsored ADR has 117.27% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is GPCR a Buy, Sell or Hold?
          Structure Therapeutics, Inc. Sponsored ADR has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Structure Therapeutics, Inc. Sponsored ADR’s price target?
            The average price target for Structure Therapeutics, Inc. Sponsored ADR is 108.46. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $145.00 ,the lowest forecast is $70.00. The average price target represents 117.27% Increase from the current price of $49.92.
              What do analysts say about Structure Therapeutics, Inc. Sponsored ADR?
              Structure Therapeutics, Inc. Sponsored ADR’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
                How can I buy shares of GPCR?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.